Disability as an outcome in MS clinical trials

Neurology

Volumn 71, Issue 9, 2008, Pages 624-631

  Ebers, G C ^a,d   Heigenhauser, L ^b   Daumer, M ^b   Lederer, C ^b   Noseworthy, J H ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Sylvia Lawry Centre for Multiple Sclerosis Research   (Germany)

^c Mayo Clinic   (United States)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; BIOLOGICAL MARKER;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; DISABILITY; DISEASE COURSE; FEMALE; HUMAN; MALE; MEASUREMENT ERROR; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT FAILURE; BIOASSAY; FACTUAL DATABASE; METHODOLOGY; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; STATISTICS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; DATABASES, FACTUAL; DISABILITY EVALUATION; DISEASE PROGRESSION; ENDPOINT DETERMINATION; HUMANS; MIDDLE AGED; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 52449117054     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000313034.46883.16     Document Type: Article

References (29)

1. Paty DW, Ebers GC. Multiple Sclerosis. Philadelphia: FA Davis Co., 1998.
2. Weinshenker BG, Bass B, Rice GPA, et al. The natural history of multiple sclerosis: a geographically based study: I: clinical course and disability. Brain 1989;112:133-146.
3. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003;348:15-23.
4. Randomised double-blind placebo-controlled study of interferonbeta1a in relapsing/remitting multiple sclerosis: PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998;352:1498-1504.
5. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiples sclerosis: results of a phase III multi-center, double-blind placebo-controlled trial: The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45:1268-1276.
6. Rice GPA, Ebers GC. Interferons in the treatment of multiple sclerosis: do they prevent the progression of the disease? Arch Neurol 1998;55:1578-1580.
7. Ebers GC. Preventing multiple sclerosis? Lancet 2001;357: 1547.
8. Johnson KP, Brooks BR, Ford CC, et al., Copolymer 1 Multiple Sclerosis Study Group. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Mult Scler 2000;6:255-266.
9. Goodkin DE. Inter and intra observer variability for grades 1.0-3.5 of the Kurtzke Expanded Disability Status Scale (EDSS). Neurology 1992;42:859-863.
10. Kappos L. Effect of drugs in secondary disease progression in patients with multiple sclerosis. Mult Scler 2004;10: S46-55.
11. Randomized trial of interferon beta-1a in secondary progressive multiple sclerosis: 1: clinical results: SPECTRIMS Study. Neurology 2001;56:1496-1504.
12. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis: European Study Group on interferon β-1b in secondary progressive MS. Lancet 1998;352:1491-1497.
13. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis: The Multiple Sclerosis Collaborative Research Group (MSCRG) [erratum 1996;40:480]. Ann Neurol 1996;39:285-294.
14. Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
15. Fillipini G, Munari L, Incorvaia B, et al. Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet 2003;361:545-552.
16. Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 2003;61:1528-1532.
17. Rio J, Nos C, Tintore M, et al. Assessment of different failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon B: implications for clinical trials. Ann Neurol 2002;52:400-446.
18. Cottrell DA, Rice GPA, Hader W, Baskerville J, Koopman WJ, Ebers GC. The natural history of multiple sclerosis: a geographically based study: 5: the clinical features and natural history of primary progressive multiple sclerosis. Brain 1999;122:625-639.
19. Liu C, Blumhardt LD. Disability outcome measures in therapeutic trails of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts. J Neurol Neurosurg Psychiatry 2000;68:450-457.
20. Rudick RA, Goodkin DE, Jacobs LD, et al. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis: The Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1997;49:358-363.
21. Francis DA, Bain P, Swan AV, Hughes RA. An assessment of disability rating scales used in multiple sclerosis. Arch Neurol 1991;48:299-301.
22. Noseworthy JH, Vandevoort MK, Ebers GC. Interrater variability with the expanded disability status scale (EDSS) and functional systems (FS) in a multiple sclerosis clinical trial. Neurology 1990;40:971-975.
23. Noseworthy JH, Ebers GC, Vandevoort MK, Farquhar RE, Yetsir R, Roberts R. The impact of blinding on a randomized double blind placebo-controlled multiple sclerosis clinical trial. Neurology 1994;44:16-20.
24. Rudick R, Antel J, Confavreux C, et al. Recommendations from the National Multiple Sclerosis Society Outcomes Assessment Task Force. Ann Neurol 1997;42:379-382.
25. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, random- ized, double-blind, placebo-controlled trial: The IFNB Multiple Sclerosis Study group. Neurology 1993;43:655-661.
26. Schwid S, Thorpe J, Sharief M, et al. Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis. Arch Neurol 2005;62:785-792.
27. Sheridan C. Fast track to MS drug. Nat Biotechnol 2004; 22:939-941.
28. Noseworthy JH, Vandervoort MK, Hopkins M, Ebers GC. A referendum on clinical trial research in multiple sclerosis: the opinion of the participants at the Jekyll Island Conference. Neurology 1989;39:977-981.
29. Noseworthy J, Kappos L, Daumer M. Competing interests in multiple sclerosis research. Lancet 2003;361: 350-351.